Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1973 4
1974 2
1976 3
1977 2
1978 2
1979 4
1980 6
1981 3
1982 5
1983 13
1984 16
1985 22
1986 11
1987 19
1988 21
1989 20
1990 28
1991 27
1992 40
1993 28
1994 25
1995 38
1996 32
1997 34
1998 29
1999 25
2000 37
2001 52
2002 70
2003 59
2004 56
2005 72
2006 110
2007 90
2008 118
2009 113
2010 165
2011 208
2012 266
2013 209
2014 232
2015 277
2016 256
2017 342
2018 435
2019 465
2020 569
2021 448
Text availability
Article attribute
Article type
Publication date

Search Results

4,582 results
Results by year
Filters applied: . Clear all
Page 1
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Papadimitrakopoulou VA, et al. Among authors: su wc. Ann Oncol. 2020 Nov;31(11):1536-1544. doi: 10.1016/j.annonc.2020.08.2100. Epub 2020 Aug 27. Ann Oncol. 2020. PMID: 32861806 Free article. Clinical Trial.
Hepatic HuR modulates lipid homeostasis in response to high-fat diet.
Zhang Z, Zong C, Jiang M, Hu H, Cheng X, Ni J, Yi X, Jiang B, Tian F, Chang MW, Su W, Zhu L, Li J, Xiang X, Miao C, Gorospe M, de Cabo R, Dou Y, Ju Z, Yang J, Jiang C, Yang Z, Wang W. Zhang Z, et al. Among authors: su w. Nat Commun. 2020 Jun 16;11(1):3067. doi: 10.1038/s41467-020-16918-x. Nat Commun. 2020. PMID: 32546794 Free PMC article.
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, Bai Y, Yuan Y, Li X, Wang X, Chen J, Ying J, Yu X, Qin S, Yuan X, Zhang T, Deng Y, Xiu D, Cheng Y, Tao M, Jia R, Wang W, Li J, Fan S, Peng M, Su W. Xu J, et al. Among authors: su w. Lancet Oncol. 2020 Nov;21(11):1500-1512. doi: 10.1016/S1470-2045(20)30496-4. Epub 2020 Sep 20. Lancet Oncol. 2020. PMID: 32966811 Clinical Trial.
De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2.
Linsky TW, Vergara R, Codina N, Nelson JW, Walker MJ, Su W, Barnes CO, Hsiang TY, Esser-Nobis K, Yu K, Reneer ZB, Hou YJ, Priya T, Mitsumoto M, Pong A, Lau UY, Mason ML, Chen J, Chen A, Berrocal T, Peng H, Clairmont NS, Castellanos J, Lin YR, Josephson-Day A, Baric RS, Fuller DH, Walkey CD, Ross TM, Swanson R, Bjorkman PJ, Gale M Jr, Blancas-Mejia LM, Yen HL, Silva DA. Linsky TW, et al. Among authors: su w. Science. 2020 Dec 4;370(6521):1208-1214. doi: 10.1126/science.abe0075. Epub 2020 Nov 5. Science. 2020. PMID: 33154107 Free PMC article.
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. Yang JC, et al. Among authors: su wc. J Thorac Oncol. 2020 Dec;15(12):1907-1918. doi: 10.1016/j.jtho.2020.09.001. Epub 2020 Sep 9. J Thorac Oncol. 2020. PMID: 32916310 Clinical Trial.
4,582 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page